DEFA14A: Patterson Companies to be Acquired by Patient Square Capital in $31.35 Per Share Deal

Patterson Companies has agreed to be acquired by Patient Square Capital for $31.35 per share in cash, taking the company private.

Summary

• Patterson Companies has entered into an agreement to be acquired by Patient Square Capital, a healthcare investment firm.
• The acquisition will result in Patterson becoming a private company, no longer publicly traded.
• Patterson shareholders will receive $31.35 per share in cash upon completion of the transaction.
• The transaction is expected to close in the fourth quarter of Patterson's fiscal year 2025, subject to shareholder and regulatory approvals.
• The company expects to operate as usual after the transaction, with no changes to its purpose, vision, values, or long-term goals.
• Employee compensation and benefits are expected to remain unchanged.
• The Patterson name and brand are expected to be retained.
• The Employee Stock Purchase Plan (ESPP) will cease to exist after the transaction, with a final share purchase on December 31, 2024.
• Shares held in the 401(k) plan with an ESOP component (KSOP) will also receive $31.35 per share.
• Long-term incentive (LTI) equity grants will be cashed out at $31.35 per share, with unvested service-based grants fully vesting and performance-based grants vesting at target levels.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook on the acquisition, emphasizing benefits for shareholders, employees, and customers. The language is optimistic about future growth and stability, but there are inherent risks associated with the transaction.

Positives

• Shareholders will receive a cash payment of $31.35 per share, providing immediate value.
• The company expects to operate as usual after the transaction, with no changes to its purpose, vision, values, or long-term goals.
• Employee compensation and benefits are expected to remain unchanged, providing stability for employees.
• The Patterson name and brand will be retained, maintaining brand recognition.
• The company believes the transaction will allow for investment in the business and accelerated growth.

Negatives

• Patterson stock will be delisted from the Nasdaq stock exchange, and shareholders will no longer trade Patterson shares in the public market.
• The Employee Stock Purchase Plan (ESPP) will be terminated after the transaction.
• Employees who were notified of a trading blackout are prohibited from trading in Patterson stock until two full business days following public disclosure of information regarding the transaction or December 13, 2024.

Risks

• The transaction is subject to shareholder and regulatory approvals, and may not be completed.
• The merger could disrupt current plans and operations or divert management's attention.
• There is a risk that the stock price may decline significantly if the merger is not completed.
• The company faces risks related to dependence on suppliers, distribution capabilities, and relationships with sales representatives.
• There are risks associated with technology obsolescence, cybersecurity, and the use of artificial intelligence.
• The company is exposed to risks in the dental and animal health supply markets, including competition and consolidation.
• The company faces risks related to litigation, government inquiries, and compliance with healthcare laws and regulations.

Future Outlook

The company expects to operate as usual after the transaction, with no changes to its purpose, vision, values, or long-term goals. They believe the transaction will allow for investment in the business and accelerated growth.

Management Comments

• Our Board of Directors determined that it is in the best interests of Patterson and its shareholders to pursue a transaction with Patient Square Capital.
• We believe this transaction will have positive benefits for Patterson, its employees, and our customers.
• Under the ownership of Patient Square Capital, we believe we will be able to invest in our business, accelerate our growth, and be well-positioned to achieve our strategic priorities.
• We expect Patterson to operate the same way after the closing of the transaction.
• It remains business as usual for all of us at Patterson.

Industry Context

This acquisition reflects a trend of private equity firms investing in healthcare companies, seeking to leverage their expertise and capital to drive growth and improve patient outcomes. The dental and animal health supply markets are competitive and consolidating, making strategic acquisitions a common approach.

Comparison to Industry Standards

• The acquisition of Patterson by Patient Square Capital is similar to other private equity buyouts in the healthcare sector, where firms seek to improve operational efficiency and drive growth in established companies.
• Comparable transactions include the acquisition of medical device and pharmaceutical companies by private equity firms, often involving a focus on operational improvements and strategic expansion.
• The $31.35 per share cash offer is a premium to the current trading price, which is typical in such acquisitions to incentivize shareholder approval.

Stakeholder Impact

• Shareholders will receive a cash payment of $31.35 per share.
• Employees are expected to see no change in compensation and benefits.
• Customers and partners are expected to experience no changes in service or relationships.
• The company believes the transaction will allow for investment in the business and accelerated growth, which could benefit all stakeholders.

Next Steps

• Prepare proxy materials for a shareholder vote.
• Schedule a meeting of shareholders to vote on the transaction.
• Make required regulatory filings.
• Complete the transaction, expected in the fourth quarter of fiscal 2025.

Key Dates

Keywords

acquisition, merger, private equity, Patient Square Capital, Patterson Companies, shareholders, delisting, ESPP, LTI, healthcare